CFO Guide · MedTech Manufacturing Finance
Medical Device Manufacturing Finance in India: The 2026 Guide to PLI, CDSCO & Capex Loans
Stop financing a regulated manufacturing asset like a trading business. Learn how device makers combine PLI incentives, device-park infrastructure support, and structured capex loans to fund cleanroom builds and tooling — before revenue ramps.
📍 CreditCares — Godrej Waterside, Sector V, Kolkata — structuring manufacturing finance for CDSCO-licensed device makers across India
9.5%–18%
Indicative p.a. rate
Up to ₹50 Cr
Facility size
5%
PLI incremental-sales incentive
80+
Banking & NBFC partners
Quick Summary
What you need to know
- What it is: Structured term loan and working capital finance for CDSCO-licensed manufacturers of medical devices and consumables, sized to your capex plan and institutional receivable cycle.
- Who should apply: Class A/B/C/D device or consumables manufacturers with a CDSCO licence, an institutional buyer base or tender pipeline, typically 2–3 years of operations.
- Maximum amount: Facilities from ₹1 Crore to ₹50 Crore, combining term loan and working capital structures.
- Interest rates: From 9.5%–12% p.a. secured, 14.5%–18% unsecured.
- Top benefits: A live ₹3,420 Crore PLI scheme paying 5% on incremental sales, Medical Device Parks infrastructure support, and SIDBI/MSME-linked backing — 14 of 27 PLI-approved applicants are MSMEs.
- Important takeaway: Most files fail from treating a capex-and-compliance business like a working-capital-only ask, or underwriting PLI money as guaranteed rather than performance-linked.
If you're setting up or scaling a medical device or consumables manufacturing unit anywhere in India, this guide covers financing structures, the current state of PLI and Device Park support, CDSCO licensing mechanics, DSCR norms, documentation, and how CreditCares structures these files.
01 · The Core Argument
Why Device Manufacturers Get Financed Differently
A medical device manufacturer isn't underwritten like a general trading or contract-manufacturing business. Two things change the picture: the regulatory moat (CDSCO licence, ISO 13485), and the buyer profile — hospitals, distributors, and tenders pay on institutional cycles, not retail cash.
| Feature | Device Manufacturing Finance | Standard Business Loan |
|---|
| Underwriting Basis | CDSCO licence class, buyer concentration, tender pipeline | Turnover and ITR only |
| Capex Structure | Term loan for cleanroom/tooling, staged to build-out | Flat lump-sum disbursement |
| Working Capital | Sized to institutional receivable cycle (45–90 days) | Generic overdraft limit |
| Regulatory Gate | CLA/SLA inspection can delay disbursement milestones | None |
| Scheme Overlay | PLI incentive, Device Park infrastructure access | Not applicable |
Expert Tip · The Regulatory Moat Is an AssetLenders increasingly treat a valid CDSCO licence and ISO 13485 certification as a positive underwriting signal — it filters out casual entrants. Lead your application with this, don't bury it in the annexures.
02 · Structures
Loan Structures Available for Device Manufacturers
| Loan Type | Covers | Range | Collateral |
|---|
| Project / Term Loan | Cleanroom, tooling, lines, plant | ₹1 Cr – ₹50 Cr | Property + project assets |
| Working Capital (CC/OD) | Receivable cycle, raw material float | ₹25 Lakh – ₹10 Cr | Often against receivables |
| Machinery Finance | Moulding, sterilisation, testing equipment | ₹25 Lakh – ₹15 Cr | The equipment financed |
| Trade Finance (LC/BG) | Import of components, capital goods | Case-by-case | Margin + collateral-linked |
| Loan Against Property | Equity from owned factory/land | Up to 65–70% of value | The property |
Practical Example · Sequencing the StructureA consumables manufacturer needed ₹4 Crore for a new line plus ₹1.5 Crore working capital for a hospital-tender contract with 60-day terms. The line was financed as a 7-year term loan; working capital was sized to the tender's actual payment cycle.
Warning · The PLI-as-Collateral MistakeSome promoters present projected PLI payouts as a DSCR revenue line. Lenders discount this heavily — PLI money is performance-linked and released with a lag. Build your base case without it.
03 · Underwriting
The 3 Pillars of Device Manufacturing Underwriting
Pillar 1 — CDSCO Licensing & Classification
Class A & B (low/moderate risk): loan licence via the State Licensing Authority — Form MD-4, approved via Form MD-6. Class C & D (high risk): via the Central Licensing Authority — Form MD-8, approved via Form MD-10, with a mandated facility inspection within 60 days. Licences are indefinite subject to a 5-year maintenance fee.
Pillar 2 — DSCR & Buyer Concentration
The Golden Rule: Lenders typically want a minimum DSCR of 1.20x–1.40x, stress-tested against a 30–60 day payment delay from your largest buyer. If over ~40% of revenue sits with a single hospital chain or tender, expect a concentration mitigant to be requested.
Pillar 3 — Certification & Compliance Track Record
ISO 13485 isn't legally mandatory for every category, but its absence is a common reason lenders price a file higher — it signals process maturity to both regulators and institutional buyers.
Did You Know?Of the 27 applications approved under the PLI Scheme for Medical Devices, 14 are from MSMEs — scale is not a prerequisite for scheme access or bankability.
04 · Case Study
Real-World Application: An Implant Manufacturer's Cleanroom Expansion
The Client
A Class C orthopedic implant manufacturer near Kolkata, CDSCO-licensed, supplying institutional hospital tenders and private distributors.
The Problem
To qualify for the PLI implants segment, the promoter needed a ₹6 Crore cleanroom expansion — but his existing bank only offered an unsecured loan far below that.
The Solution
- Restructured as a project/term loan against the factory property, sized to actual construction and equipment cost.
- Built the DSCR case on existing tender revenue alone — explicitly excluding projected PLI income.
- Routed to a lender comfortable with the CLA inspection timeline already built into the disbursement schedule.
The Result
A ₹6 Crore secured term loan at 10.5% p.a., staged to construction milestones — with the PLI incentive now a bonus to debt paydown, not a load-bearing assumption.
05 · Decision Matrix
Decision Matrix: Choosing the Right Product
06 · Process
The Loan Approval Journey
Timelines run longer than a standard business loan when a CLA/SLA inspection sits on the critical path — plan for it rather than being surprised by it.
Day 1
Application & CDSCO File Review
Licence class, DPR, and promoter financials submitted.
Day 5
DSCR & Buyer-Concentration Assessment
Cash flow modelled excluding scheme incentives from the base case.
Day 10
Site Visit & Valuation
Cross-checked against the CLA's 60-day inspection window if applicable.
Day 15
Legal & Compliance Verification
Title checks, CDSCO documentation, ISO certification confirmed.
Day 20
Sanction Letter
Term loan + working capital split confirmed.
Day 25+
Staged Disbursement
Funds released against construction/equipment milestones.
07 · Lender Comparison
Comparing the Market: Banks vs. NBFCs
| Lender Type | Rates | Speed | Regulatory-Gating Comfort | CIBIL Req. |
|---|
| PSU & Large Private Banks | 9.5%–12% | 20–30 days | High — familiar with CLA/SLA timelines | 700+ |
| NBFCs | 12%–18% | 10–20 days | Variable — some price in a delay premium | 650+ |
The CreditCares AdvantageWe route your file to lenders who've already financed CDSCO-licensed manufacturers — so a pending CLA inspection reads as a known milestone, not an unexplained delay.
08 · Preparation
Eligibility & Document Checklists
| Document Category | What's Needed |
|---|
| Regulatory | CDSCO licence & certifications (ISO 13485 where held) |
| Project | Detailed project report / expansion plan |
| Financials | 3 years' financials & ITR |
| Revenue Evidence | Order book / tender documents |
| Banking | 12 months' bank statements |
Check Your Exact Loan Eligibility Today →
09 · Financial Math
Loan Amount vs. EMI Impact
| Facility Type | Rate | Tenure |
|---|
| Unsecured | 14.5% – 18.0% p.a. | 12 – 48 months |
| Secured (with property) | 9.5% – 12.0% p.a. | Up to 15 years |
Expert TipOn a ₹6 Crore secured facility, the gap between 9.5% and 12% is roughly ₹9–11 Lakhs a year in interest — often worth the extra weeks it takes to qualify for the lower band.
10 · Live Scheme Status
PLI, Device Parks & Tax Incentives — What's Actually Live in 2026
Sourced from a Lok Sabha disclosure dated 24 July 2026
| Scheme | Outlay | Status as of July 2026 |
|---|
| PLI Scheme for Medical Devices | ₹3,420 Cr (FY22-23 to FY26-27) | ₹266.64 Cr released; 27 approved (14 MSMEs); ₹1,153.07 Cr actual investment |
| Medical Device Parks Scheme | ₹300 Cr | ₹209.80 Cr disbursed, ₹177.98 Cr utilised |
| SMDI — MIS-RID | — | ₹101.50 Cr approved |
| SMDI — CFMDC | — | ₹88.67 Cr approved, ₹20.62 Cr released |
PLI Mechanics: 5% incentive on incremental sales (over FY2019-20 base) across four segments — cancer care & radiotherapy; radiology, imaging & nuclear imaging; anaesthetics, cardio-respiratory & renal care; and all implants. Products already in production include MRI/CT scanners, LINACs, mammography systems, C-arms, ultrasound, heart valves and stents.
Warning · Section 115BAB Is Currently Closed to New EntrantsSection 115BAB's 15% concessional tax rate required production to commence by 31 March 2024 — that deadline was not extended in the FY26 Budget, and industry is lobbying for reintroduction in FY27. Verify current status with your CA before assuming this applies.
11 · Cost Breakdown
Fees and Charges You Must Know
| Fee Type | Typical Range |
|---|
| Processing Fee (Secured) | 0.5% – 1.5% |
| Processing Fee (Unsecured) | 1.5% – 3% |
| Foreclosure Penalty | 0% – 4% of principal |
| Valuation & Legal Checks | ₹15,000 – ₹75,000 |
| Stamp Duty (if secured) | State-specific |
12 · Interactive Tools
Free Manufacturing Finance Calculators
Model your facility structure before approaching a lender. Explore all CreditCares tools: Term Loan EMI Calculator · DSCR Checker (excluding scheme income) · Working Capital Cycle Estimator.
13 · Pitfalls
Common Mistakes That Get Manufacturing Loans Rejected
- Applying before the CDSCO licence stage is documented, even informally.
- Underwriting PLI incentive income into the DSCR base case.
- Ignoring buyer concentration risk when 40%+ of revenue sits with one buyer.
- Underestimating cleanroom/tooling cost overruns mid-construction.
- Financing capex through working capital instead of a properly termed project loan.
14 · Myth vs Fact
Myth vs. Fact in Device Manufacturing Finance
Myth"PLI incentive money arrives as soon as I hit the sales threshold."
FactOnly ₹266.64 Cr of the ₹3,420 Cr outlay had been released as of FY24-25 — disbursal lags. Plan cash flow without depending on timing.
Myth"Any small manufacturer can get space in a Medical Device Park."
FactAccess typically runs through state nodal agencies with allocation criteria, not a walk-in facility.
Myth"New device manufacturers still get the 15% tax rate under Section 115BAB."
FactThe window closed 31 March 2024 and hasn't reopened as of mid-2026, though industry is lobbying for its return.
Myth"An unsecured business loan is enough to fund a real manufacturing project."
FactCleanroom/tooling capex is a project-finance need with a staged drawdown — unsecured working-capital loans are usually the wrong instrument.
15 · FAQ
Frequently Asked Questions
What is the maximum loan amount available for medical device manufacturing in India?
Facilities typically range from ₹1 Crore to ₹50 Crore, combining a term loan for capex with working capital sized to the institutional receivable cycle.
Do I need a CDSCO licence before applying for a manufacturing loan?
Not fully granted, but lenders want clear evidence of where you stand in the MD-4 (Class A/B) or MD-8 (Class C/D) process.
Is the PLI scheme for medical devices still open to new applicants?
The scheme runs through FY2026-27 with a fixed ₹3,420 Cr outlay; verify current tranche/application status directly with the scheme administrator (DoP&P).
Can I count projected PLI incentive income toward my loan eligibility?
Most lenders heavily discount or exclude it from DSCR, since it's performance-linked and released with a lag. Treat it as accelerated debt paydown, not collateral.
What's the difference between Class A/B and Class C/D licensing for financing purposes?
Class A/B goes through the State Licensing Authority with a faster path; Class C/D requires Central Licensing Authority approval with a mandatory 60-day inspection — lenders build this into disbursement timelines.
Is Section 115BAB's 15% tax rate available to a device manufacturer starting production in 2026?
No — the deadline to commence production was 31 March 2024 and hasn't been extended as of mid-2026. Confirm current status with your CA.
What collateral is typically required for a device manufacturing term loan?
Secured facilities are typically backed by the factory property and project assets; unsecured options exist at smaller ticket sizes but at meaningfully higher rates.
Does CreditCares charge any upfront fee for arranging manufacturing finance?
No. CreditCares charges zero upfront fee — our fee is charged only after your loan is sanctioned and disbursed.
Author Profile & Trust Signals
Who Wrote and Reviewed This Guide
AS
Ananya Sharma
Senior Credit Advisor, CreditCares
Structures manufacturing and healthcare-sector project finance for CDSCO-licensed businesses across West Bengal and pan-India.
AR
Anirban Roy, FCA
Reviewer — Finance Expert
Chartered Accountant reviewing tax treatment, scheme mechanics, and lending compliance. Data verified July 2026.
₹2,000 Cr+
Disbursed across all categories
500+
Corporate clients funded
Since 2012
Godrej Waterside, Kolkata
16 · Conclusion
Conclusion & Strategic Next Steps
Medical device manufacturing sits at a genuine inflection point in India — a live ₹3,420 Crore PLI outlay, a Device Parks programme building shared infrastructure, and steadily rising institutional demand. But none of that changes the fundamentals: a CDSCO-licensed manufacturer needs project finance structured around construction milestones and a buyer-concentration-aware DSCR, not a generic business loan stretched to cover a capex need it was never sized for.
CreditCares has facilitated over ₹2,000 Crore in loan disbursals for 500+ corporate clients across 80+ banks and NBFCs, with zero upfront fee.
CreditCares is a private loan consultancy and Direct Selling Agent (DSA), not a bank, NBFC, or government body. Loan approval, sanction amount, interest rate and terms are at the sole discretion of the respective bank or NBFC. Scheme figures cited are sourced from public government disclosures as of July 2026 and are subject to change — verify current status on official portals. Zero upfront fee — we do not charge for sanction guarantees and do not guarantee approval.